PK and Safety of BR1015-A (Fimasartan/Indapamide) in Healthy Volunteers

Phase 1, randomised, open-label trial of fimasartan and indapamide in essential hypertension (2 arms), sponsored by Boryung. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration of Fimasartan at 48 hours, Area under the plasma concentration-time curve from time zero to the last measurable concentration of Indapamide at 72 hours and 2 more. Planned start Apr 2026; status: not yet recruiting.